Literature DB >> 30616035

Serum level of macrophage migration inhibitory factor predicts severity and prognosis in patients with ischemic stroke.

Chao-Wei Wang1, Peng-Ju Ma2, Yang-Yang Wang2, Ming Yang2, Lin-Lin Su1, Shuo Wang1, Yan-Xia Liu3, Bin Yuan1, Jian-Hua Zhao4.   

Abstract

OBJECTIVE: To evaluate whether the macrophage migration inhibitory factor (MIF) level in serum of ischemic stroke patients was associated with their clinical severity and early outcome.
METHODS: During February 2017-March 2018, consecutive patients admitted to our hospital because of first-ever ischemic stroke were identified. The prognostic value of MIF was set for predicting the outcome of these patients at discharge. The results were compared with existing methods, including National Institutes of Health Stroke Scale (NIHSS) score and validated indicators.
RESULTS: 289 patients were enrolled. The serum level of all patients was determined (median: 20.6 ng/ml). At admission, 131 patients (45.3%) were evaluated as minor stroke (NIHSS < 5). When serum level of MIF was increased by each 1 ng/ml, the unadjusted and adjusted risk of moderate-to-high clinical severity was elevated by 5% (OR = 1.05 [95% CI: 1.01-1.09], P = 0.006) and 3% (1.03 [1.00-1.08], P = 0.02), respectively. At discharge, 82 patients (28.4%) had poor functional outcomes. The median serum level of MIF was lower in group with good outcomes than that observed in poor outcomes (19.4[15.8-24.2] vs. 24.0[19.9-29.4] ng/ml; P < 0.001). When serum level of MIF was increased by each 1 ng/ml, the unadjusted and adjusted risk of poor outcomes was elevated by 9% (1.09 [1.05-1.13], P < 0.001) and 6% (1.06 [1.02-1.10], P < 0.01), respectively.
CONCLUSIONS: High MIF levels are independently related to the moderate to high clinical severity in ischemic stroke patients, as well as the poor outcome at discharge.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Functional recovery; Ischemic stroke; Macrophage migration inhibitory factor; Prognosis

Mesh:

Substances:

Year:  2019        PMID: 30616035     DOI: 10.1016/j.cyto.2018.11.029

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

1.  The Association Between Serum Macrophage Migration Inhibitory Factor and Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage.

Authors:  Xiaobo Yang; Jianhua Peng; Jinwei Pang; Weifeng Wan; Chuanhong Zhong; Tangming Peng; Kunyang Bao; Yong Jiang
Journal:  Neurotox Res       Date:  2019-07-02       Impact factor: 3.911

2.  Neuroprotective Effect of Macrophage Migration Inhibitory Factor (MIF) in a Mouse Model of Ischemic Stroke.

Authors:  Ji Ae Kim; Ye Young Kim; Seung Hak Lee; Chul Jung; Mi Hee Kim; Dae Yul Kim
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

3.  Stroke Dysbiosis Index (SDI) in Gut Microbiome Are Associated With Brain Injury and Prognosis of Stroke.

Authors:  Geng-Hong Xia; Chao You; Xu-Xuan Gao; Xiu-Li Zeng; Jia-Jia Zhu; Kai-Yu Xu; Chu-Hong Tan; Ruo-Ting Xu; Qi-Heng Wu; Hong-Wei Zhou; Yan He; Jia Yin
Journal:  Front Neurol       Date:  2019-04-24       Impact factor: 4.003

4.  Macrophage Migration Inhibitory Factor Alters Functional Properties of CA1 Hippocampal Neurons in Mouse Brain Slices.

Authors:  Eric Bancroft; Rahul Srinivasan; Lee A Shapiro
Journal:  Int J Mol Sci       Date:  2019-12-31       Impact factor: 5.923

Review 5.  Monocyte Transmodulation: The Next Novel Therapeutic Approach in Overcoming Ischemic Stroke?

Authors:  Joohyun Park; Ji Young Chang; Jong Youl Kim; Jong Eun Lee
Journal:  Front Neurol       Date:  2020-10-22       Impact factor: 4.003

6.  Antagonism of Macrophage Migration Inhibitory Factory (MIF) after Traumatic Brain Injury Ameliorates Astrocytosis and Peripheral Lymphocyte Activation and Expansion.

Authors:  M Karen Newell-Rogers; Susannah K Rogers; Richard P Tobin; Sanjib Mukherjee; Lee A Shapiro
Journal:  Int J Mol Sci       Date:  2020-10-09       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.